Clinical trial · Interventional
The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic cancer is a very poor prognosis and has a high mortality rate. The clinical results have improved somewhat with the combination therapy of chemotherapy as the first-line treatment. However, effective secondary chemotherapy after these first-line treatment failures is limited. Recently, FOLFIRINOX has been used in patients with locally advanced or metastatic pancreatic cancer who have good performance in Korea. Gemcitabine + nab-paclitaxel (GnP) as a second-line treatment after FOLFIRINOX may be expected to be considerable. The aim of this study was to evaluate the efficacy of GnP as a second-line treatment after failed FOLFIRINOX treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Effect | — | UNRESOLVED | — |
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy (Gemcitabine + nab-paclitaxel) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Gemcitabine + nab-paclitaxel
- description
- Case with chemotherapy (Gemcitabine + nab-paclitaxel)
- interventionNames
- Drug: Chemotherapy (Gemcitabine + nab-paclitaxel)
Primary outcomes (1)
- measure
- survival rate
- timeFrame
- 6 months
- description
- survival rate at 6 months after 2nd line chemotherapy
Secondary outcomes (4)
- measure
- overall survival
- timeFrame
- till death or follow-up loss or end of study up to 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
1. Inclusion criteria 1. Patient whose age is 20 years or older 2. ECOG Performance Status 0-2 3. Pathologically confirmed pancreatic adenocarcinoma 4. Patients with locally advanced or distant metastasis status 5. Patients who had undergone primary chemotherapy with previous FOLFIRINOX and whose disease progress was confirmed 6. Patients whose consent was obtained (non-insurance agreement) 2. Exclusion Criteria 1. Those who can not obtain consent 2. Those who refuse chemotherapy 3. ECOG Performance Status 3 or higher 4. Multiple organ failure is accompanied 5. Severe comorbidities other than cancer that do not expect a sufficient survival period over 1 month 6. Allergy to the test drug
References
Publications (1)
- DERIVEDHuh G, Lee HS, Choi JH, Lee SH, Paik WH, Ryu JK, Kim YT, Bang S, Lee ES. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. Ther Adv Med Oncol. 2021 Nov 10;13:17588359211056179. doi: 10.1177/17588359211056179. eCollection 2021. PMID 34790261